Breaking News Instant updates and real-time market news.

ADSK

Autodesk

$134.09

(0.00%)

, ANTM

Anthem

$232.23

(0.00%)

09:45
05/15/18
05/15
09:45
05/15/18
09:45

Jana adds Autodesk position in Q1, sells out of Facebook

Barry Rosenstein's Jana Partners disclosed in a regulatory filing its holdings as of March 31, 2018. Jana made 23 new buys during the first quarter, including, by size of position, Autodesk (ADSK), Anthem (ANTM), Boston Scientific (BSX), Lam Research (LRCX) and Dr Pepper Snapple (DPS). Jana exited 14 positions during the quarter, including by size of previous position, EQT Corporation (EQT), Liberty Broadband (LBRDA), Comcast (CMCSA), Facebook (FB) and Iqvia (IQVIA). Jana increased its stake in four holdings, Pinnacle Foods (PF), Jack in the Box (JACK), Northrop Grumman (NOC) and Conagra Brands (CAG). The fund reduced its stake in nine holdings, including by size First Data (FDC), Zimmer Biomet (ZBH), D.R. Horton (DHI), Tiffany (TIF) and PTC (PTC). Jana's top holdings as of March, in order of size, were Tiffany, HD Supply (HDS), Zimmer Biomet, Pinnacle Foods and Jack in the Box.

ADSK

Autodesk

$134.09

(0.00%)

ANTM

Anthem

$232.23

(0.00%)

BSX

Boston Scientific

$29.70

-0.17 (-0.57%)

LRCX

Lam Research

$203.82

-0.2 (-0.10%)

DPS

Dr Pepper Snapple

$119.55

-0.14 (-0.12%)

EQT

EQT Corporation

$51.76

0.08 (0.15%)

LBRDA

Liberty Broadband

$71.65

(0.00%)

CMCSA

Comcast

$31.83

-0.31 (-0.96%)

FB

Facebook

$185.00

-1.68 (-0.90%)

IQV

Iqvia

$102.46

-0.47 (-0.46%)

PF

Pinnacle Foods

$62.85

-0.4 (-0.63%)

JACK

Jack in the Box

$89.31

(0.00%)

NOC

Northrop Grumman

$318.72

(0.00%)

CAG

Conagra Brands

$37.66

-0.08 (-0.21%)

FDC

First Data

$19.47

-0.17 (-0.87%)

ZBH

Zimmer Biomet

$114.19

-0.95 (-0.83%)

DHI

D.R. Horton

$42.75

-0.74 (-1.70%)

TIF

Tiffany

$102.94

-0.02 (-0.02%)

PTC

PTC

$85.71

-0.55 (-0.64%)

HDS

HD Supply

$39.92

(0.00%)

  • 15

    May

  • 15

    May

  • 15

    May

  • 15

    May

  • 16

    May

  • 17

    May

  • 18

    May

  • 22

    May

  • 24

    May

  • 24

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

ADSK Autodesk
$134.09

(0.00%)

05/14/18
DBAB
05/14/18
NO CHANGE
Target $150
DBAB
Buy
Autodesk price target raised to $150 from $136 at Deutsche Bank
Deutsche Bank analyst Alex Tout raised his price target on Autodesk to $150 as he previewed the company Q1 report, stating that he thinks the company gave greater clarity on the pricing power in the core business during its analyst day and he believes a significant reset around Cloud has been a positive for the stock. Tout maintains a Buy rating on Autodesk shares.
04/30/18
KEYB
04/30/18
NO CHANGE
Target $150
KEYB
Overweight
Autodesk price target raised to $150 from $144 at KeyBanc
KeyBanc analyst Monika Garg raised her price target for Autodesk to $150 from $144 saying that despite concerns its revenue ramp to FY21 could be difficult, her analysis gives her confidence a 23% CAGR over the next three years is achievable. The analyst reiterates an Overweight rating on the shares.
04/19/18
OPCO
04/19/18
NO CHANGE
Target $150
OPCO
Outperform
Autodesk price target raised to $150 from $145 at Oppenheimer
Oppenheimer analyst Koji Ikeda raised his price target for Autodesk to $150 from $145 as he believes the construction digital replat-forming opportunity should act as a driver for future growth and free cash flow generation, which increases his confidence that the 2020 growth and profitability targets are achievable. Autodesk is his top large-cap stock pick, and the analyst is incrementally more bullish on the name following a recent round of construction industry checks, which lend support to his long-term thesis that the business is one of the best-positioned software vendors for future share gains of construction industry technology spend. Ikeda reiterates an Outperform rating on the shares.
05/15/18
MSCO
05/15/18
NO CHANGE
Target $160
MSCO
Overweight
Autodesk price target raised to $160 from $150 at Morgan Stanley
Morgan Stanley analyst Keith Weiss said he now has greater confidence in billings growth at Autodesk after doing a "deep dive" on the primary drivers of its long-term subscription growth. Citing his new analyst, Weiss raised his price target on Autodesk to $160 and maintains an Overweight rating on the stock.
ANTM Anthem
$232.23

(0.00%)

04/26/18
04/26/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Buy from Neutral at UBS, to Outperform from Neutral at Macquarie, and to Neutral from Underweight at Atlantic Equities. 2. Boeing (BA) upgraded to Buy from Hold at Societe Generale. 3. Chipotle (CMG) upgraded to Buy from Neutral at BTIG, to Buy from Hold at Canaccord, to Neutral from Sell at Guggenheim, and to Market Perform from Underperform at Cowen. 4. Wex (WEX) upgraded to Buy from Neutral at Citi with analyst Peter Christiansen saying despite rallying 28% in the past six months, the stock should "grind further on continued organic momentum, though importantly on favorable margin dynamics." 5. Anthem (ANTM) upgraded to Overweight from Neutral at JPMorgan with analyst Gary Taylor saying he continues to be comfortable with the near-term trajectory of medical cost trends for the health insurance industry and maintains a long-term preference to own payors over providers. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/26/18
JPMS
04/26/18
UPGRADE
JPMS
Overweight
Anthem upgraded to Overweight from Neutral at JPMorgan
04/26/18
JPMS
04/26/18
UPGRADE
Target $287
JPMS
Overweight
Anthem upgraded to Overweight with $287 price target at JPMorgan
JPMorgan analyst Gary Taylor upgraded Anthem to Overweight from Neutral and raised his price target for the shares to $287 from $261. The analyst continues to be comfortable with the near-term trajectory of medical cost trends for the health insurance industry and maintains a long-term preference to own payors over providers. He believes Anthem's Q1 performance "set the stage" for 2018 earnings upside.
04/26/18
BERN
04/26/18
NO CHANGE
Target $332
BERN
Outperform
Anthem price target raised to $332 from $312 at Bernstein
Bernstein analyst Lance Wilkes raised his price target for Anthem to $332 from $312 after the company announced "solid" Q1 results. The analyst reiterates an Outperform rating on the shares.
BSX Boston Scientific
$29.70

-0.17 (-0.57%)

03/19/18
MSCO
03/19/18
NO CHANGE
Target $33
MSCO
Overweight
Boston Scientific price target raised to $33 from $30 at Morgan Stanley
Morgan Stanley analyst David Lewis raised his price target on Boston Scientific to $33 and kept his Overweight rating, citing the company's outperforming growth profile and balance sheet flexibility. Lewis says the company can sustain a 6%-7% organic expansion with its pipeline and a shift to higher growth end markets, which are ineffectively reflected in valuation. The analyst adds that while the selloff was driven by concerns around Lotus Edge, the product is "more of a call option" based on the company's core performance.
05/14/18
STFL
05/14/18
NO CHANGE
Target $33
STFL
Buy
Boston Scientific mesh issues likely overstated by 60 Minutes, says Stifel
Stifel analyst Rick Wise commented on the "60 Minutes" story regarding Boston Scientific transvaginal mesh products and associated lawsuits, calling the report "unsettling...but likely overstated." He notes that the company has reached or is near settlement on 47,500 of the known 49,500 mesh legal claims, has a $1.5B legal reserve for the matter and has said it expects the majority of the remaining mesh claims to be resolved in 2018. Wise keeps a Buy rating and $33 price target on Boston Scientific shares.
03/26/18
WELS
03/26/18
NO CHANGE
WELS
IPR decision a 'nice' win for Edwards Lifesciences, says Wells Fargo
Wells Fargo analyst Lawrence Biegelsen notes USPTO has determined that all claims of the '608 patent that have been asserted against Edwards Lifesciences (EW) are invalid, which the analyst sees as an important victory for the company because the '608 patent is one of Boston Scientific's (BSX) key transcatheter valve patents. While Boston Scientific will appeal the USPTO's decision on the '608 patent, Biegelsen's patent consultant believes the company's chances of overturning the decision are very low.
03/22/18
ADAM
03/22/18
NO CHANGE
Target $35
ADAM
Buy
Canaccord remains a buyer of Boston Scientific following NxThera deal
Canaccord analyst Jason Mills said he would remain a buyer of Boston Scientific following the company's announcement that it will buy NxThera, which which has developed treatments for endo-urological conditions like benign prostatic hyperplasia, or BPH. In a research note to investors, Mills said Boston Scientific raises the long-term growth potential of its Urology and Pelvic Health portfolio, ultimately being in position to sell both surgical and MIS BPH therapeutic modalities.Mills, who has a Buy rating and $35 price target on Boston Scientific shares, expects the company to become "increasingly" active in M&A, noting that he likes the company's strategic vision and potential, and is "bullish" about the growth prospects of its core franchises.
LRCX Lam Research
$203.82

-0.2 (-0.10%)

04/26/18
NEED
04/26/18
NO CHANGE
Target $28
NEED
Buy
Ultra Clean price target lowered to $28 from $34 at Needham
Needham analyst Y. Edwin Mok lowered his price target on Ultra Clean Holdings to $28 to reflect the "lower comp multiples" but kept his Buy rating after the company's Q1 earnings beat. Mok notes that the expectations for the quarter were low considering the reduction in shipment outlook by the company's large customer Lam Research (LRCX), but Ultra Clean was able to top the Street's model. The analyst adds that he awaits more signs of growth from its inorganic vector, but sees Ultra Clean executing well in its organic strategy.
05/15/18
COWN
05/15/18
INITIATION
Target $258
COWN
Outperform
Lam Research initiated with an Outperform at Cowen
Cowen analyst Kris Sankar initiated Lam Research with an Outperform rating, citing secular trends like increasing memory content in storage, mobile, and autos. He believes its cash generation will help fuel stock buybacks and potentially an increase in its dividend. Sankar has a $258 price target on Lam Research shares.
05/14/18
05/14/18
UPGRADE

Buy
Citi upgrades Lam Research to Buy ahead of strong 2019 equipment spending
As previously reported, Citi analyst Atif Malik upgraded Lam Research (LRCX) to Buy from Neutral, as he believes his concerns about weak NAND memory spending this year are now mostly priced-in and he sees investments planned by Samsung and others leading to higher year-over-year NAND equipment spending growth in 2019. He also assumes strong DRAM equipment spending this year, Malik tells investors. Malik noted that his 2019 wafer fab equipment spending forecast of $61B is above the consensus view of $58B. He still identifies Applied Materials (AMAT) as his number one U.S. semi capital equipment pick, placing KLA-Tencor (KLAC) at number two.
05/14/18
SBSH
05/14/18
UPGRADE
SBSH
Buy
Lam Research upgraded to Buy from Neutral at Citi
DPS Dr Pepper Snapple
$119.55

-0.14 (-0.12%)

03/21/18
BMOC
03/21/18
NO CHANGE
Target $122
BMOC
Market Perform
Dr Pepper Snapple analyst day profiled rising coffee consumption, says BMO
BMO Capital analyst Amit Sharma keeps his Market Perform rating and $122 price target on Keurig Dr Pepper but notes that the company's analyst day has positioned it as an "attractive play" amid rising coffee consumption in multiple categories, formats, and channels. Sharma adds that despite his neutral stance on the stock, he is more positive about the company's ability to produce the $600M in cost synergies while also pointing to further margin expansion in the standalone Keurig Green Mountain business.
03/19/18
RBCM
03/19/18
UPGRADE
RBCM
Outperform
Dr Pepper Snapple upgraded to Outperform from Sector Perform at RBC Capital
03/19/18
RBCM
03/19/18
UPGRADE
Target $135
RBCM
Outperform
Dr Pepper Snapple upgraded to Outperform at RBC Capital on Keurig deal benefits
As reported earlier, RBC Capital analyst Nik Modi upgraded Dr Pepper Snapple to Outperform from Sector Perform and raised his price target to $135 from $125. Modi says that some investors have struggled to justify the strategic rationale of the company's Keurig deal, but he sees "several value creation drivers" including leverage in the growing coffee category, improvements for the core Keurig brand, and the prospects for higher cash flow conversion.
03/19/18
03/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Unilever (UN, UL) upgraded to Neutral from Sell at Goldman Sachs with the firm's analyst saying valuation reflects growth challenges. 2. AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies with analyst Ian Hilliker saying the company is at a "turning point." 3. Dr Pepper Snapple (DPS) upgraded to Outperform from Sector Perform at RBC Capital saying that some investors have struggled to justify the strategic rationale of the company's Keurig deal, but he sees "several value creation drivers" including leverage in the growing coffee category, improvements for the core Keurig brand, and the prospects for higher cash flow conversion. 4. Oshkosh (OSK) upgraded to Buy from Hold while Cummins (CMI) upgraded to Hold from Sell at Deutsche Bank. 5. HarborOne Bancorp (HONE) upgraded to Buy from Hold at Sandler O'Neill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
EQT EQT Corporation
$51.76

0.08 (0.15%)

03/21/18
BOFA
03/21/18
DOWNGRADE
Target $66
BOFA
Neutral
EQT Midstream Partners downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Dennis Coleman downgraded EQT Midstream Partners (EQM) to Neutral and cut its price target to $66 from $81 citing uncertainty related to the EQT Corporation (EQT) split.
02/15/18
02/15/18
NO CHANGE

EQT Corporation reports Q4 non-GAAP EPS 76c, consensus 24c
Reports Q4 revenue $1.3B, consensus $958.79M.
03/21/18
BOFA
03/21/18
DOWNGRADE
Target $24
BOFA
Neutral
EQT GP downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Dennis Coleman downgraded EQT GP (EQGP) to Neutral and cut its price target to $24 from $32 citing uncertainty related to the EQT Corporation (EQT) split.
02/14/18
WOLF
02/14/18
UPGRADE
WOLF
Outperform
EQT Corporation upgraded to Outperform from Peer Perform at Wolfe Research
LBRDA Liberty Broadband
$71.65

(0.00%)

12/13/17
BUCK
12/13/17
INITIATION
Target $119
BUCK
Buy
Liberty Broadband initiated with a Buy at Buckingham
Buckingham analyst Matthew Harrigan Liberty Broadband (LBRDA) with a Buy and $119 price target to reflect alignment with Charter Communications (CHTR), which was initiated with a Buy rating, ownership.
CMCSA Comcast
$31.83

-0.31 (-0.96%)

05/08/18
05/08/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Comcast (CMCSA) downgraded to Neutral from Overweight at Atlantic Equities. 2. Zillow (Z, ZG) downgraded to Sector Perform from Outperform at RBC Capital with analyst Mark Mahaney citing the recent stock price appreciation. 3. XL Group (XL) downgraded to Sector Perform from Outperform at RBC Capital with analyst Mark Dwelle saying the company's first quarter earnings did not contain any red flags around the sale of the company to AXA (AXAHY), which is on track to close in late second quarter or in the third quarter. 4. Ionis Pharmaceuticals (IONS) downgraded to In Line from Outperform at Evercore ISI with analyst Josh Schimmer citing the safety concerns around volanesorsen discussed in the latest FDA briefing documents, which also "dismantled the company's claims" that the treatment leads to benefits in pancreatis. 5. Sapiens (SPNS) downgraded to Market Perform from Outperform at William Blair with analyst Justin Furby saying consensus estimates for 2019 could be a "too aggressive." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/08/18
ATLE
05/08/18
DOWNGRADE
ATLE
Neutral
Comcast downgraded to Neutral from Overweight at Atlantic Equities
05/10/18
OPCO
05/10/18
NO CHANGE
Target $42
OPCO
Outperform
Comcast acquisition of Fox would make strategic, financial sense, says Oppenheimer
Oppenheimer analyst Timothy Horan notes that press reports stated Comcast (CMCSA) has lined up $60B in financing to make an all-cash offer for Fox's (FOXA) entertainment assets, representing a 15% premium to Disney's (DIS) offer. While he thinks this has caused half the 30% decline in Comcast's stock year to date, the analyst believes it does make strategic and financial sense, and Comcast has a great track record on acquisitions. Horan thinks a joint NBC/Fox is a content powerhouse while expanding the company's presence in Europe through Sky (SKYAY), and slashing OTT video risk. The analyst reiterates an Outperform rating and $42 price target on Comcast's shares.
04/09/18
NOMU
04/09/18
NO CHANGE
Target $40
NOMU
Neutral
Comcast price target lowed to $40 from $45 at Nomura Instinet
Nomura Instinet analyst Jeffrey Kvaal lowered his price target for Comcast shares to $40 to reflect reduced buyback expectations. The analyst, however, says the "sky is not falling." The analyst, while continuing to prefer mobile over fixed, views the 15% pullback in Comcast shares as an overreaction. He expects the company to offer investors "some relief" on its Q1 call. Kvaal keeps a Neutral rating on Comcast.
FB Facebook
$185.00

-1.68 (-0.90%)

05/10/18
BMOC
05/10/18
NO CHANGE
Target $45
BMOC
Outperform
Match Group price target lowered to $45 from $49 at BMO Capital
BMO Capital analyst Daniel Salmon lowered his price target on Match Group (MTCH) to $45, citing the recent sell-off in the stock price after the Facebook (FB) announcement that it is entering into the online dating market. Salmon keeps his Outperform rating however, stating that the valuation discount is too great because he does not expect a "material disruption" to Tinder's use of the Facebook login. The analyst adds that 75% of Tinder users decline to login through Facebook, suggesting that people prefer to keep some space between their social and dating lives.
05/10/18
UBSW
05/10/18
UPGRADE
Target $48
UBSW
Buy
Match Group upgraded to Buy at UBS
As previously reported, UBS analyst Eric Sheridan upgraded Match Group (MTCH) to Buy from Neutral. The analyst said the recent risks and fears of competition from Facebook (FB) are priced in and its solid Q1 results show the trends for its core brands remain intact. Sheridan maintained his $48 price target on Match Group shares.
05/10/18
DBAB
05/10/18
NO CHANGE
Target $43
DBAB
Buy
Match Group price target raised to $43 from $33 at Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley raised his price target for Match Group (MTCH) to $43 and keeps a Buy rating on the shares. The company's "strong" Q1 results were "overwhelmed' by concerns over Facebook (FB), Walmsley tells investors in a research note. He believes multiple expansion could remain challenged until investors have visibility into Facebook's product and adoption trends.
05/11/18
BNCH
05/11/18
NO CHANGE
Target $182
BNCH
Buy
IAC price target raised to $182 from $176 at Benchmark
Benchmark analyst Daniel Kurnos raised his price target on IAC (IAC) to $182 from $176 after its "strong" quarter, which he said was "headlined by blowout revenue and earnings" from Match (MTCH) and continued strong growth at Angi Homeservices (ANGI). He believes risk to IAC from a Facebook (FB) dating challenge seems largely factored in at current levels, Kurnos added.
IQV Iqvia
$102.46

-0.47 (-0.46%)

03/07/18
RHCO
03/07/18
UPGRADE
RHCO
Buy
Iqvia upgraded to Buy from Hold at SunTrust
03/07/18
RHCO
03/07/18
UPGRADE
Target $130
RHCO
Buy
Iqvia upgraded to Buy at SunTrust on attractive stock price entry point
As reported earlier, SunTrust analyst Sandy Draper upgraded Iqvia to Buy from Hold and raised his price target to $130 from $110. Draper says his prior focus was "mistakenly" on the organic growth and book-to-bill trends rather than the earnings growth as a function of capital deployment. He believes that earnings growth can continue for another 2-3 years, while the sell-off in the stock price after Q4 results offers an attractive entry opportunity for a company that has high visibility, EBITDA growth, "superb FCF conversion, and a management commitment to capital redeployment".
01/18/18
EVER
01/18/18
INITIATION
Target $112
EVER
Outperform
Iqvia initiated with an Outperform at Evercore ISI
Evercore initiated Iqvia with an Outperform and $112 price target.
04/13/18
GSCO
04/13/18
UPGRADE
GSCO
Buy
Iqvia upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Robert Jones upgraded Iqvia Holdings to Buy with a slightly reduced price target of $114. The analyst views consensus expectations as conservative and the company's Next-Gen clinical offering as differentiated. He wants to add more Contract Research Organization exposure heading into the Q1 earnings reports "despite Biopharma M&A jitters."
PF Pinnacle Foods
$62.85

-0.4 (-0.63%)

04/20/18
JEFF
04/20/18
NO CHANGE
Target $67
JEFF
Buy
Conagra a natural buyer of Pinnacle Foods, says Jefferies
Jana Partners is likely to push for sale of Pinnacle Foods (PF) or consolidation opportunities, Jefferies analyst Akshay Jagdale tells investors in a research note after the activist disclosed a stake. He believes Conagra Brands (CAG) is one of the natural buyers and that a potential combination with Pinnacle would be "significantly accretive." Jagdale assumes a purchase price of $72 per share for Pinnacle, which represents a 30% premium to the current price. The analyst keeps a Buy rating on the shares with a $67 price target.
04/20/18
WBLR
04/20/18
NO CHANGE
WBLR
Outperform
Pinnacle takeout price could be $75-$80 per share, says William Blair
William Blair analyst Jon Andersen says that if a sale of Pinnacle Foods were to be the outcome following the activist stake by Jana Partners, previous deals in the food space suggest a takeout price of $75-$80 per share. Jana is "keen on unlocking additional value from Pinnacle's portfolio and operations," Andersen tells investors in a research note. He keeps an Outperform rating on Pinnacle Foods.
04/30/18
04/30/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wayfair (W) downgraded to Neutral from Outperform at Wedbush with analyst Seth Basham citing rising CAC and profitability pressures. 2. JetBlue (JBLU) downgraded to Neutral from Overweight at JPMorgan with analyst Jamie Baker saying a lack of pilot progress, a "paucity of international RASM exposure," and the "uphill battle" to rein in non-labor costs represent "burdens" for JetBlue shareholders. 3. Owens Corning (OC) downgraded to Outperform from Top Pick at RBC Capital with analyst Michael Eisen citing the company's first quarter earnings miss. 4. Colgate-Palmolive (CL) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Dara Mohsenian saying the company posted weak organic sales in Q1 and pointed out on its associated call that emerging markets are decelerating. 5. Pinnacle Foods (PF) downgraded to Neutral from Buy at Buckingham with analyst Eric Larson citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/30/18
BUCK
04/30/18
DOWNGRADE
BUCK
Neutral
Pinnacle Foods downgraded to Neutral from Buy at Buckingham
Buckingham analyst Eric Larson downgraded Pinnacle Foods citing valuation and maintained a $62 price target.
JACK Jack in the Box
$89.31

(0.00%)

05/07/18
05/07/18
DOWNGRADE

Mixed
Follow-up: Jack in the Box downgraded to Mixed on competition at OTR Global
As previously reported, OTR Global downgraded Jack in the Box to Mixed from Positive. The firm's checks with managers indicate increased competition and a mixed response to the Cholula Buttery Jack is pressuring transactions and sales.
05/07/18
OTRG
05/07/18
DOWNGRADE
OTRG
Mixed
Jack in the Box downgraded to Mixed from Positive at OTR Global
05/10/18
SPHN
05/10/18
NO CHANGE
Target $120
SPHN
Overweight
GrubHub deal with Jack in the Box 'one of many to come,' says Stephens
After GrubHub (GRUB) announced a partnership to provide delivery for hundreds of Jack in the Box (JACK) locations, Stephens analyst Will Slabaugh noted that the deal is not exclusive but he believes it will be "one of many to come" for GrubHub with large national chains. He maintains an Overweight rating and $120 price target on GrubHub shares.
03/26/18
03/26/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Adobe (ADBE) downgraded to Market Perform from Outperform at JMP Securities with analyst Patrick Walravens saying he believes the shares are fairly valued after having risen 69% in 2017 and a further 21% year-to-date. 2. Dover (DOV) downgraded to Neutral from Overweight at JPMorgan with analyst Steve Tusa saying a lack of near-term catalysts makes the risk/reward profile no longer attractive. 3. AMD (AMD) downgraded to Negative from Neutral at Susquehanna with analyst Christopher Rolland saying he confirmed Bitmain has developed an ASIC for Ethereum mining, which he believes accounted for roughly 20% of AMD's sales. 4. Jack in the Box (JACK) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst John Glass saying he sees limited upside and ongoing top-line risk. 5. Willis Towers Watson (WLTW) downgraded to Underperform from Neutral at BofA/Merrill with analyst Jay Cohen saying while Willis' organic growth rebounded in 2017, its inconsistent margin performance detracts a bit from his confidence in the company's near-term earnings power. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NOC Northrop Grumman
$318.72

(0.00%)

05/08/18
05/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Advance Auto Parts (AAP) upgraded to Overweight from Neutral at Atlantic Equities with analyst Sam Hudson saying he expects an inflection in comps and margins when the company reports towards the end of May. 2. Northrop Grumman (NOC) and Harris (HRS) were upgraded to Conviction Buy from Buy at Goldman Sachs. 3. Louisiana-Pacific (LPX) upgraded to Buy from Neutral at DA Davidson with analyst Steven Chercover saying while the oriented strand board prices are near or at their peak, the company's blend of earnings power, balance sheet liquidity, and sales mix offer a "compelling value" at the stock's current price level. 4. Columbia Property (CXP) upgraded to Buy from Neutral at Goldman Sachs with analyst Andrew Rosivach saying he sees an attractive entry point at current share levels. 5. Loma Negra (LOMA) upgraded to Buy from Hold at HSBC and to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/26/18
MSCO
04/26/18
NO CHANGE
MSCO
Defense weakness due to correction, not change in narrative, says Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani noted that Defense stocks are down about 6% and underperforming an already weak market in the last few days, which he finds particularly surprising given the Q1 EPS beats from General Dynamics (GD), Lockheed Martin (LMT) and Northrop Grumman (NOC). He attributes the underperformance to three dynamics: outperformance year-to-date prior to the selloff; the catalyst of large budget step-ups having materialized; and fuller valuation, which has being corrected. None of these are fundamental, added Lalwani, saying he is still constructive on Lockheed, Raytheon (RTN) and Northrop.
04/26/18
BERN
04/26/18
NO CHANGE
Target $352
BERN
Market Perform
Northrop Grumman price target lowered to $352 from $369 at Bernstein
Bernstein analyst Douglas Harned lowered his price target for Northrop Grumman to $352 from $369 primarily on lowering his market multiple after recent broad market declines. The analyst reiterates a Market Perform rating on the shares.
05/08/18
GSCO
05/08/18
UPGRADE
GSCO
Conviction Buy
Northrop Grumman upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Noah Poponak added Northrop Grumman to his firm's Conviction List while keeping a Buy rating on the shares. Northrop has the "strongest" product portfolio in large cap Defense that will allow it to outgrow peers organically for the next ten years, Poponak tells investors in a research note. He says the "valuation reset" has put the stock back into "top pick territory." He has a $410 price target for the shares.
CAG Conagra Brands
$37.66

-0.08 (-0.21%)

03/20/18
RBCM
03/20/18
NO CHANGE
Target $45
RBCM
Outperform
Conagra Brands is outperforming its U.S. food peers, says RBC Capital
RBC Capital analyst David Palmer writes in his research note titled "Weathering the Storm" that Conagra is executing and surpassing its own expectations at a time when some U.S. food companies are breaking from their long term growth trends to stabilize their sales declines. Palmer acknowledges that Conagra is facing some profit headwinds for Q3 due to higher freight costs and lighter volumes after a weather-related stock-up in Q2, but also points to accelerating base sales and volume growth in the frozen foods segment. The analyst keeps his Outperform rating and $45 price target on Conagra.
04/20/18
JPMS
04/20/18
NO CHANGE
JPMS
Overweight
Pinnacle Foods is a likely takeout candidate, says JPMorgan
After Jana Partners disclosed a 9.5% activist stake in Pinnacle Foods (PF), JPMorgan analyst Ken Goldman reiterates his belief that the company is a likely takeout candidate. The most logical potential buyer for Pinnacle would be Conagra (CAG) because putting the two frozen food manufacturers together would generate "unusually powerful" cost synergies, Goldman tells investors in a research note. The analyst also sees are other credible potential suitors for Pinnacle, such as Kraft Heinz (KHC). Goldman has Overweight ratings on all three names.
03/06/18
SPHN
03/06/18
NO CHANGE
Target $125
SPHN
Equal Weight
FTC action likely seen as limited negative for J.M. Smucker, says Stephens
After the FTC filed an administrative complaint challenging J.M. Smucker's (SJM) planned acquisition of the Wesson oil brand from Conagra (CAG), Stephens analyst Farha Aslam said the oils category is mature and competitive so an increased presence in the space was not considered optimal. Given that, she thinks the FTC action will likely be seen as a limited negative for Smucker. Aslam maintains her Equal Weight rating on J.M. Smucker shares.
FDC First Data
$19.47

-0.17 (-0.87%)

04/24/18
MZHO
04/24/18
INITIATION
Target $19
MZHO
Buy
First Data initiated with a Buy at Mizuho
Mizuho analyst Thomas McCrohan started First Data Corporation with a Buy rating and $19 price target. The recovery within the company's core North American merchant processing segment is underway, McCrohan tells investors in a research note. He sees the unit, which represents 48% of total segment revenue, returning to mid-single digit organic revenue growth in 2019. The analyst also thinks First Data's continued deleveraging will eventually lead to a credit upgrade.
04/30/18
CHLM
04/30/18
NO CHANGE
Target $30
CHLM
Buy
First Data price target raised to $30 from $25 at Craig-Hallum
Craig-Hallum analyst Brad Berning raised his price target for First Data to $30 following this morning's Q1 results. The analyst keeps a Buy rating on the shares.
05/01/18
CHLM
05/01/18
NO CHANGE
Target $30
CHLM
Buy
First Data price target raised to $30 from $25 at Craig-Hallum
Craig-Hallum analyst Bradley Berning raised his price target for First Data to $30 from $25, citing the quarterly beat from stronger underlying organic growth. The analyst reiterates a Buy rating on the shares.
04/24/18
04/24/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. First Data (FDC) initiated with a Buy at Mizuho. 2. Allergan (AGN) resumed with a Buy at Citi. 3. Alder Biopharmaceuticals (ALDR) initiated with a Neutral at Goldman Sachs. 4. ConvergeOne (CVON) initiated with an Outperform at Cowen. 5. Aeglea BioTherapeutics (AGLE) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ZBH Zimmer Biomet
$114.19

-0.95 (-0.83%)

04/27/18
CANT
04/27/18
NO CHANGE
Target $140
CANT
Overweight
Zimmer Biomet risk/reward compelling at current levels, says Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou says that following management commentary, he's more confident Zimmer Biomet is on track to restore full supply by the end of Q2, leading to accelerating growth in the second half of 2018. The company's earnings guidance fell short of Street expectations and 2019 estimates will come, but management is prudently managing investor expectations, Bijou tells investors in a post-earnings research note. He views the stock's risk/reward as compelling and reiterates an Overweight rating on the name.
04/17/18
PIPR
04/17/18
NO CHANGE
PIPR
J&J commentary positive for pure-play spine names, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien is out discussing derivative calls following Johnson & Johnson's (JNJ) Q1 results. The orthopedic market looked relatively stable, though Hips were notably softer than expected, O'Brien tells investors in a research note. He believes Stryker (SYK) is "clearly taking market share," which he views as an incremental negative for Zimmer Biomet (ZBH). On Spine, some U.S. weakness was expected, but J&J's results could be viewed as concerning given continued weakness since Q3 of 2017, the analyst adds. He thinks the end markets "are ok" and the commentary on J&J losing share benefits pure-play spine names NuVasive (NUVA), Globus Medical (GMED), SeaSpine (SPNE) and K2M Group (KTWO). He believes the pure-plays continue to out-innovate and take share despite the weakness in the overall category. Johnson & Johnson's results also show that the U.S. lens market remains strong and is shifting to 1-Days lenses from weeklies/monthlies, which is a positive for Cooper Companies (COO), O'Brien contends. Lastly, the analyst says the decline in J&J's U.S. diabetes franchise from the Animas exit was faster than expected. This is good for the pump names Insulet (PODD) and Tandem Diabetes (TNDM) and a slight negative for Dexcom (DXCM) as some of those will end up at Medtronic (MDT), O'Brien argues. He continues to believe that both Insulet and Tandem "will gain more than their fair share" of Animas patients.
03/23/18
BARD
03/23/18
DOWNGRADE
BARD
Neutral
Zimmer Biomet downgraded to Neutral from Outperform at Baird
04/02/18
EVER
04/02/18
INITIATION
Target $115
EVER
In Line
Zimmer Biomet initiated with an In Line at Evercore ISI
Evercore ISI analyst Vijay Kumar started Zimmer Biomet with an In Line rating and $115 price target. Zimmer is losing share in knees due to supply constrains whole smaller players have gained in spine, Kumar tells investors in a research note.
DHI D.R. Horton
$42.75

-0.74 (-1.70%)

03/07/18
03/07/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Domino's Pizza (DPZ) upgraded to Buy from Hold at Argus with analyst John Staszak saying he believes that the company's stock price does not adequately reflect its prospects for earnings growth and rising market share based on the management's objective of 6%-8% annual store count growth. 2. Donaldson (DCI) upgraded to Buy on valuation at Gabelli with analyst Brian Sponheimer citing valuation following the quarterly report. 3. Quest Diagnostics (DGX) upgraded to Buy from Hold at Argus with analyst Jasper Hellweg saying he has a positive view of the company's cash generation, cost controls, and share repurchases, while also pointing to its first dividend increase since the first quarter of 2016, last month. 4. D.R. Horton (DHI) upgraded to Outperform from Neutral at Wedbush with analyst Jay McCanless saying he believes the recent pullback appears overdone. 5. Ooma (OOMA) upgraded to Neutral from Underperform at BofA/Merrill with analyst Nikolay Beliov saying the home Telo business is showing signs of acceleration, the Office business continues to growth, and Voxter adds capabilities to target larger companies, which will improve mix. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/26/18
03/26/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Intel (INTC) and Analog Devices (ADI) upgraded to Outperform from Market Perform at Raymond James. 2. D.R. Horton (DHI) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Bouley saying he sees the company as well positioned to absorb volume demand while maintaining gross margins. 3. RBS (RBS) upgraded to Buy from Hold at Deutsche Bank with the firm saying the recent underperformance of shares has brought an attractive entry point. 4. MetLife (MET) upgraded to Overweight from Neutral at Atlantic Equities. 5. Dollar Tree (DLTR) upgraded to Overweight from Neutral at Piper Jaffray with analyst Peter Keith saying he believes the company is making "sensible investments" with Family Dollar to drive comp growth improvement into 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/07/18
03/07/18
UPGRADE
Target $50

Outperform
D.R. Horton upgraded to Outperform at Wedbush
As previously reported, Wedbush analyst Jay McCanless upgraded D.R. Horton to Outperform from Neutral, with a $50 price target, as he believes the recent pullback appears overdone.
03/26/18
LEHM
03/26/18
UPGRADE
Target $52
LEHM
Overweight
D.R. Horton upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Matthew Bouley upgraded D.R. Horton to Overweight with a $52 price target. The analyst sees the company as well positioned to absorb volume demand while maintaining gross margins. He expects new construction volumes to remain relatively unaffected as interest rates rise and thinks the recent weakness in the shares provides upside potential.
TIF Tiffany
$102.94

-0.02 (-0.02%)

05/04/18
OPCO
05/04/18
NO CHANGE
Target $115
OPCO
Outperform
Tiffany price target raised to $115 from $105 at Oppenheimer
Oppenheimer analyst Brian Nagel reiterated his Outperform rating on Tiffany & Co and raised his price target on shares to $115 from $105. In a research note to investors, Nagel said that a more aggressive strategic enhancement strategy is still underway and expected to yield "even better" results. He also noted that macro tailwinds are strengthening, including a weaker U.S. dollar and indications of building global consumer wealth, and that, while no longer cheap, Tiffany shares continue to underappreciate the potential for an improving sales and EPS trajectory at the specialty retailer.
03/16/18
JEFF
03/16/18
NO CHANGE
Target $125
JEFF
Buy
Jefferies recommends long-term view on Tiffany, maintains Buy rating
Jefferies analyst Randal Konik listed several things he liked about Tiffany's Q4 report - including its first positive quarterly comp performance in over two years and the fact that it seems product "newness" is taking hold - as well as some things he did not like - such as persistent European weakness and slower flow through of tax rate benefits. While the market may focus on deceleration in January and operating margin pressure, he recommends looking past the near-term to the company's positioning for accelerated long-term growth. Konik keeps a Buy rating and $125 price target on Tiffany shares.
04/05/18
LOOP
04/05/18
UPGRADE
Target $113
LOOP
Buy
Tiffany upgraded to Buy from Hold at Loop Capital
Loop Capital analyst Laura Champine upgraded Tiffany to Buy from Hold and raised her price target to $113 from $103. Champine says her initial meeting with the company's new CEO Alessandro Bogliogo added to her confidence that Tiffany's efforts to "revitalize" revenues will be successful, adding that the downbeat market reaction to Q4 earnings was "overblown". The analyst forecasts Q1 comps to grow 4.2% - the highest quarterly growth rate since Q3 of 2015 - and also notes Tiffany's "attractive" valuation of 22-times her FY18 EPS forecast.
04/05/18
04/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Overweight from Equal Weight at Barclays with analyst Geoffrey Meacham saying he believes the company will continue to take share in first-line lung cancer, driven by positive KN-189 and KN-042 data. 2. Acuity Brands (AYI) upgraded to Outperform from Market Perform at JMP Securities with analyst Joseph Osha saying he believes the stock is finally trading at a "reasonable valuation based on reasonable expectations." 3. AMD (AMD) upgraded to Buy from Hold at Stifel with analyst Kevin Cassidy citing valuation and the company's margin expansion potential. 4. Tiffany (TIF) upgraded to Buy from Hold at Loop Capital with analyst Laura Champine saying her initial meeting with the company's new CEO Alessandro Bogliogo added to her confidence. 5. Citi (C) and Wells Fargo (WFC) were upgraded to Buy from Neutral at UBS. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PTC PTC
$85.71

-0.55 (-0.64%)

04/23/18
BREN
04/23/18
NO CHANGE
Target $100
BREN
Buy
PTC price target raised to $100 from $80 at Berenberg
Berenberg analyst Gal Munda raised his price target for PTC to $100 ahead of the company's investor day in June. Management could raise their fiscal 2021 free cash flow target of $525M by 10%, Munda tells investors in a research note. He notes that PTC's revenue, profitability, and cash metrics are now coming ahead of guidance. The analyst recommends buying the stock ahead of the investor day and keeps a Buy rating on the name.
04/16/18
RBCM
04/16/18
NO CHANGE
Target $85
RBCM
Outperform
PTC price target raised to $85 from $80 at RBC Capital
RBC Capital analyst Matthew Hedberg raised his price target on PTC (PTC) to $85 and kept his Outperform rating ahead of the company's Q2 earnings. Hedberg says PTC should should build on its strong start to the year with continued execution amid a "solid macro environment". The analyst points to better traction for the company's Internet of Things products as well as potential benefits from its partnership with Microsoft's (MSFT) Azure, along with "above-market-growth from the solutions business on improved direct/indirect selling".
04/18/18
MUFG
04/18/18
NO CHANGE
Target $67
MUFG
Neutral
PTC price target raised to $67 from $50 at MUFG
MUFG analyst Stephen Bersey raised his price target on PTC to $67 after the company's Q1 earnings beat that showed "continued strength in its core business". Bersey adds that PTC appears to be near completion in its subscription model shift , anticipating mid-single digit revenue growth going forward. The analyst keeps his Neutral rating on PTC longer term on concerns around the growth potential of its non-core business units.
04/19/18
BARD
04/19/18
NO CHANGE
Target $95
BARD
Outperform
PTC price target raised to $95 from $83 at Baird
Baird analyst Rob Oliver raised his price target on PTC to $95 from $83 following Q2 results. The analyst noted the company reported in-line bookings and maintained the full-year bookings outlook and noted Q3 guidance was above consensus. Oliver reiterated his Outperform rating on PTC shares.
HDS HD Supply
$39.92

(0.00%)

03/15/18
RHCO
03/15/18
UPGRADE
Target $48
RHCO
Buy
HD Supply upgraded to Buy at SunTrust on potential for spin-offs
As reported earlier, SunTrust analyst Keith Hughes upgraded HD Supply to Buy from Hold while also raising his price target to $48 from $42. Hughes says the current valuation on the stock is too low at 10.7-times enterprise value to EBITDA, with his new price target taking that valuation to the upper middle of the distribution group range. The analyst justifies higher multiple based on his segment sum-of-the-parts analysis of Facilities Maintenance and Commercial/Industrial units, speculating that a spinoff to realize value could occur.
03/19/18
GSCO
03/19/18
INITIATION
Target $41
GSCO
Neutral
HD Supply assumed with a Neutral at Goldman Sachs
Goldman Sachs analyst Evelyn Chow assumed coverage of HD Supply Holdings with a Neutral rating and $41 price target. The analyst sees several near-term headwinds for the company and believes now is not the right time to own the shares. Chow initiated the Industrial Distributors sector with a neutral stance.
04/06/18
DBAB
04/06/18
INITIATION
Target $45
DBAB
Buy
HD Supply resumed with a Buy at Deutsche Bank
Deutsche Bank analyst Karen Lau resumed coverage of HD Supply with a Buy rating and $45 price target. The analyst believes investor skepticism following the company's operational and cost issues creates a favorable risk/reward for the shares.
03/15/18
03/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. HD Supply (HDS) upgraded to Buy from Hold at SunTrust with analyst Keith Hughes saying the current valuation on the stock is too low at 10.7-times enterprise value to EBITDA, with his new price target taking that valuation to the upper middle of the distribution group range. 2. Viacom (VIAB) upgraded to Buy from Hold at Needham with analyst Laura Martin saying the stock's forward PE valuation at 8.2-times is 15%-30% below peers mainly due to Paramount's losses. 3. Akamai (AKAM) upgraded to Sector Weight from Underweight at KeyBanc with analyst Brandon Nispel saying Akamai's ability to expand margins is greater than he anticipated and that fears surrounding growth are "unlikely to come to fruition near term." 4. Aon plc (AON) upgraded to Buy from Neutral at Goldman Sachs while Willis Towers Watson (WLTW) was upgraded to Neutral from Sell. 5. Exxon Mobil (XOM) upgraded to Buy from Reduce at HSBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

KORS

Michael Kors

$68.71

0.33 (0.48%)

12:45
05/25/18
05/25
12:45
05/25/18
12:45
Options
Michael Kors call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 26

    Jun

12:45
05/25/18
05/25
12:45
05/25/18
12:45
General news
Breaking General news story  »

Week of 5/25 Baker-Hughes…

ZTCOY

ZTE Corp.

$0.00

(0.00%)

, ACIA

Acacia Communications

$33.68

1.49 (4.63%)

12:39
05/25/18
05/25
12:39
05/25/18
12:39
Periodicals
Trump administration says deal struck on ZTE Corp., NYT reports »

The Trump administration…

ZTCOY

ZTE Corp.

$0.00

(0.00%)

ACIA

Acacia Communications

$33.68

1.49 (4.63%)

OCLR

Oclaro

$9.13

0.25 (2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

  • 12

    Jun

  • 10

    Sep

NBR

Nabors Industries

$7.27

-0.54 (-6.91%)

12:35
05/25/18
05/25
12:35
05/25/18
12:35
Options
Nabors Industries put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEP

PepsiCo

$100.19

0.01 (0.01%)

12:31
05/25/18
05/25
12:31
05/25/18
12:31
Hot Stocks
PepsiCo confirms agreement to acquire Bare Snacks »

PepsiCo announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEP

PepsiCo

$100.29

0.11 (0.11%)

12:29
05/25/18
05/25
12:29
05/25/18
12:29
Periodicals
PepsiCo to acquire baked fruit and veggie snack maker Bare Foods, NYT reports »

PepsiCo will acquire…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$55.19

0.41 (0.75%)

12:27
05/25/18
05/25
12:27
05/25/18
12:27
Periodicals
EEOC investigates age discrimination claims against Intel, WSJ reports »

The U.S. Equal Employment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROST

Ross Stores

$77.43

-5.52 (-6.65%)

12:20
05/25/18
05/25
12:20
05/25/18
12:20
Options
Notable ratio spread in Ross Stores as shares slump on earnings »

Notable ratio spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$28.45

-4.52 (-13.71%)

, FL

Foot Locker

$53.39

7.01 (15.11%)

12:18
05/25/18
05/25
12:18
05/25/18
12:18
General news
On The Fly: Top stock stories at midday »

The S&P 500 opened…

GPS

Gap

$28.45

-4.52 (-13.71%)

FL

Foot Locker

$53.39

7.01 (15.11%)

HLF

Herbalife Nutrition

$48.96

-4.89 (-9.08%)

IEP

Icahn Enterprises

$69.33

0.14 (0.20%)

FCAU

Fiat Chrysler

$21.86

-0.4 (-1.80%)

DGX

Quest Diagnostics

$106.60

5.71 (5.66%)

UNH

UnitedHealth

$244.87

2.14 (0.88%)

ROST

Ross Stores

$77.38

-5.57 (-6.71%)

ADSK

Autodesk

$132.89

-5.87 (-4.23%)

AAL

American Airlines

$45.31

1.76 (4.04%)

LUV

Southwest

$53.21

2 (3.91%)

DAL

Delta Air Lines

$55.80

1.39 (2.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 30

    May

  • 30

    May

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 26

    Jun

  • 29

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
05/25/18
05/25
12:17
05/25/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$162.03

-0.01 (-0.01%)

, DIA

Diamonds Fund ETF

$247.61

-0.29 (-0.12%)

12:16
05/25/18
05/25
12:16
05/25/18
12:16
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

For the week, fund flows…

IWM

iShares Trust Russell 2000 Index Fund

$162.03

-0.01 (-0.01%)

DIA

Diamonds Fund ETF

$247.61

-0.29 (-0.12%)

XLF

Financial Select Sector

$27.87

-0.08 (-0.29%)

XLE

Energy Select Sector SPDR

$74.03

-2.51 (-3.28%)

IVV

iShares Core S&P 500

$274.29

-0.46 (-0.17%)

SPY

SPDR S&P 500 ETF Trust

$272.41

-0.46 (-0.17%)

JNK

SPDR Barclays High Yield Bond

$35.72

-0.03 (-0.08%)

EMB

iShares JP Morgan USD Emerging Markets Bond ETF

$109.63

0.28 (0.26%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.29

0.235 (0.20%)

EFV

iShares MSCI EAFE Value ETF

$54.37

-0.49 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
05/25/18
05/25
12:16
05/25/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$12.00

-1.04 (-7.98%)

12:15
05/25/18
05/25
12:15
05/25/18
12:15
Options
QEP Resources put volume heavy and directionally bearish »

Bearish flow noted in QEP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

AIPT

Precision Therapeutics

$1.00

0.01 (1.01%)

, SKLN

Ticker changed to AIPT

$0.00

(0.00%)

12:10
05/25/18
05/25
12:10
05/25/18
12:10
Hot Stocks
Skyline Medical says products approved on DAPA contract »

Skyline Medical sent the…

AIPT

Precision Therapeutics

$1.00

0.01 (1.01%)

SKLN

Ticker changed to AIPT

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$64.84

1.39 (2.19%)

12:05
05/25/18
05/25
12:05
05/25/18
12:05
Options
Kellogg call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

12:05
05/25/18
05/25
12:05
05/25/18
12:05
General news
Treasury Option Action: some bullish positioning »

Treasury Option Action:…

GIFI

Gulf Island Fabrication

$10.40

-0.05 (-0.48%)

11:56
05/25/18
05/25
11:56
05/25/18
11:56
Hot Stocks
Gulf Island Fabrication awarded 3300HP towboat newbuild project with option »

Gulf Island Fabrication…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$102.96

0.86 (0.84%)

, TWX

Time Warner

$94.04

-0.22 (-0.23%)

11:54
05/25/18
05/25
11:54
05/25/18
11:54
Hot Stocks
Box Office Battle: 'Solo' looking to shoot first, take out 'Deadpool 2' »

Disney's (DIS) Han…

DIS

Disney

$102.96

0.86 (0.84%)

TWX

Time Warner

$94.04

-0.22 (-0.23%)

VIAB

Viacom

$27.69

0.4 (1.47%)

CMCSK

Comcast

$0.00

(0.00%)

LGF.A

Lionsgate

$24.50

1.17 (5.02%)

LGF.B

Lionsgate

$23.05

1 (4.54%)

SNE

Sony

$46.56

0.11 (0.24%)

VIA

Viacom

$32.45

0.6 (1.88%)

FOX

21st Century Fox

$38.81

0.31 (0.81%)

FOXA

21st Century Fox

$39.25

0.32 (0.82%)

CMCSA

Comcast

$31.99

0.35 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKTR

Nektar

$80.14

-0.44 (-0.55%)

11:53
05/25/18
05/25
11:53
05/25/18
11:53
Conference/Events
Nektar to hold 2018 ASCO Investor Event »

In conjunction with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 05

    Jun

  • 12

    Jun

CELG

Celgene

$79.23

-0.25 (-0.31%)

11:50
05/25/18
05/25
11:50
05/25/18
11:50
Conference/Events
Celgene to hold analyst and investor event from ASCO Annual Meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 02

    Jun

  • 03

    Jun

  • 05

    Jun

  • 13

    Jun

NKE

Nike

$72.43

0.29 (0.40%)

11:50
05/25/18
05/25
11:50
05/25/18
11:50
Options
Notable spread in Nike as shares reach new highs »

Notable spread in Nike as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

AFSI

AmTrust

$13.76

0.035 (0.26%)

11:49
05/25/18
05/25
11:49
05/25/18
11:49
Hot Stocks
Icahn says ISS recommends shareholders vote against AmTrust going-private deal »

Carl Icahn issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LRLCY

L'Oreal

$0.00

(0.00%)

11:46
05/25/18
05/25
11:46
05/25/18
11:46
Hot Stocks
L'Oreal to acquire Pulp Riot Hair Color »

L'Oreal announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$38.70

2.72 (7.56%)

11:45
05/25/18
05/25
11:45
05/25/18
11:45
Options
Roku Inc (Class A Stock) call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:45
05/25/18
05/25
11:45
05/25/18
11:45
Conference/Events
Barclays biopharmaceutical analyst to hold an analyst/industry conference call »

U.S. Biopharmaceuticals…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.